论文部分内容阅读
1商品名Clolar2开发与上市厂商本品由美国Bioenvision公司开发,于2005年1月11日在美国首次上市。3适应证本品适用于至少接受两种治疗后复发的急性淋巴细胞白血病或难治性急性淋巴细胞白血病患儿。
1 Name Clolar2 development and listing of manufacturers This product was developed by the United States Bioenvision company, in the January 11, 2005 the first time in the United States. 3 indications This product is suitable for at least two relapsed after receiving treatment of acute lymphoblastic leukemia or refractory children with acute lymphoblastic leukemia.